Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study

Arthur J. Matas, Thiagarajan Ramcharan, Steven Paraskevas, Kristen J. Gillingham, David L. Dunn, Rainer W G Gruessner, Abhinav Humar, Raja Kandaswamy, John S. Najarian, William D. Payne, David E R Sutherland

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Steroids are associated with significant postoperative complications (hypertension, cosmetic changes, bone loss, hyperlipidemia, diabetes, and cataracts). Most develop early; in addition, late post-transplant steroid withdrawal in kidney transplant recipients has been associated with increased acute rejection (AR). To obviate these problems, we studied outcome of a protocol of rapid discontinuation of prednisone (RDS) (steroids stopped on POD6). Between November 1, 1999 and October 31, 2000, 51 adult living donor (LD) first transplant recipients (2 HLA-id, 28 non-id relative, 21 LURD) were immunosuppressed with thymoglobulin (1.25 mg/kg intraoperatively and then qdx4); prednisone (P) (500 mg methylprednisolone intraoperatively, 1 mg/kg × 1 day, 0.5 mg/kg × 2 days, 0.25 mg/kg × 2days, then d/c); MMF, 1 g b.i.d.; and CSA, 4mg/kg b.i.d. adjusted to achieve levels of 150-200 ng/mL (by HPLC). Exclusion criteria were delayed graft function or 1° disease requiring P. Minimum follow-up was 5.5 months (range 5.5 to 17.5 months). Outcome was compared vs. previous cohorts of LD recipients immunosuppressed with P/AZA/ CSA (n=171) or P/MMF/CSA (n = 43) (both without antibody induction). Results: For the RDS group, average CSA level (±S.E.) at 3 and 6 months was 190±12 and 180±9; avg. MMF dose, 1.7±0.1 g and 1.7±0.1 g. There was no significant difference in 6- and 12-month actuarial patient survival, graft survival and rejection-free graft survival between recipients on the RDS protocol vs. historical controls. For RDS recipients, actuarial 6- and 12-month rejection-free graft survival was 87%. Of the 51 RDS recipients, five (10%) have had AR (at 20 days, 1 month, 3 months, 3 months, and 3.5 months post-transplant). After treatment, all five were maintained on 5mg P; there have been no second AR episodes. Two additional recipients were started on 5 mg P due to low white blood count (WBC) and low/no MMF. Of the 51 grafts, one has failed (death with function). Average serum Cr level (±S.E.) at 3 and 6 months for RDS recipients was 1.7±0.5 (NS vs. historical controls). Conclusion: For low-risk LD recipients, a kidney transplant with an RDS protocol does not increase risk of AR or graft loss. Future studies will need to be done to assess AR rates with an RDS protocol in cadaver transplant recipients and in recipients with delayed graft function.

Original languageEnglish (US)
Pages (from-to)278-283
Number of pages6
JournalAmerican Journal of Transplantation
Volume1
Issue number3
DOIs
StatePublished - Sep 2001
Externally publishedYes

Fingerprint

Living Donors
Prednisone
Kidney Transplantation
Steroids
Graft Survival
Delayed Graft Function
Transplants
Graft Rejection
Kidney
Dilatation and Curettage
Methylprednisolone
Hyperlipidemias
Cadaver
Cosmetics
Cataract
High Pressure Liquid Chromatography
Hypertension
Bone and Bones
Survival
Antibodies

Keywords

  • Kidney transplant
  • Steroid discontinuation

ASJC Scopus subject areas

  • Immunology

Cite this

Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation : A Pilot Study. / Matas, Arthur J.; Ramcharan, Thiagarajan; Paraskevas, Steven; Gillingham, Kristen J.; Dunn, David L.; Gruessner, Rainer W G; Humar, Abhinav; Kandaswamy, Raja; Najarian, John S.; Payne, William D.; Sutherland, David E R.

In: American Journal of Transplantation, Vol. 1, No. 3, 09.2001, p. 278-283.

Research output: Contribution to journalArticle

Matas, AJ, Ramcharan, T, Paraskevas, S, Gillingham, KJ, Dunn, DL, Gruessner, RWG, Humar, A, Kandaswamy, R, Najarian, JS, Payne, WD & Sutherland, DER 2001, 'Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study', American Journal of Transplantation, vol. 1, no. 3, pp. 278-283. https://doi.org/10.1034/j.1600-6143.2001.001003278.x
Matas, Arthur J. ; Ramcharan, Thiagarajan ; Paraskevas, Steven ; Gillingham, Kristen J. ; Dunn, David L. ; Gruessner, Rainer W G ; Humar, Abhinav ; Kandaswamy, Raja ; Najarian, John S. ; Payne, William D. ; Sutherland, David E R. / Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation : A Pilot Study. In: American Journal of Transplantation. 2001 ; Vol. 1, No. 3. pp. 278-283.
@article{74b6ccfd3834447fa0f876f2a76a1ac3,
title = "Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study",
abstract = "Steroids are associated with significant postoperative complications (hypertension, cosmetic changes, bone loss, hyperlipidemia, diabetes, and cataracts). Most develop early; in addition, late post-transplant steroid withdrawal in kidney transplant recipients has been associated with increased acute rejection (AR). To obviate these problems, we studied outcome of a protocol of rapid discontinuation of prednisone (RDS) (steroids stopped on POD6). Between November 1, 1999 and October 31, 2000, 51 adult living donor (LD) first transplant recipients (2 HLA-id, 28 non-id relative, 21 LURD) were immunosuppressed with thymoglobulin (1.25 mg/kg intraoperatively and then qdx4); prednisone (P) (500 mg methylprednisolone intraoperatively, 1 mg/kg × 1 day, 0.5 mg/kg × 2 days, 0.25 mg/kg × 2days, then d/c); MMF, 1 g b.i.d.; and CSA, 4mg/kg b.i.d. adjusted to achieve levels of 150-200 ng/mL (by HPLC). Exclusion criteria were delayed graft function or 1° disease requiring P. Minimum follow-up was 5.5 months (range 5.5 to 17.5 months). Outcome was compared vs. previous cohorts of LD recipients immunosuppressed with P/AZA/ CSA (n=171) or P/MMF/CSA (n = 43) (both without antibody induction). Results: For the RDS group, average CSA level (±S.E.) at 3 and 6 months was 190±12 and 180±9; avg. MMF dose, 1.7±0.1 g and 1.7±0.1 g. There was no significant difference in 6- and 12-month actuarial patient survival, graft survival and rejection-free graft survival between recipients on the RDS protocol vs. historical controls. For RDS recipients, actuarial 6- and 12-month rejection-free graft survival was 87{\%}. Of the 51 RDS recipients, five (10{\%}) have had AR (at 20 days, 1 month, 3 months, 3 months, and 3.5 months post-transplant). After treatment, all five were maintained on 5mg P; there have been no second AR episodes. Two additional recipients were started on 5 mg P due to low white blood count (WBC) and low/no MMF. Of the 51 grafts, one has failed (death with function). Average serum Cr level (±S.E.) at 3 and 6 months for RDS recipients was 1.7±0.5 (NS vs. historical controls). Conclusion: For low-risk LD recipients, a kidney transplant with an RDS protocol does not increase risk of AR or graft loss. Future studies will need to be done to assess AR rates with an RDS protocol in cadaver transplant recipients and in recipients with delayed graft function.",
keywords = "Kidney transplant, Steroid discontinuation",
author = "Matas, {Arthur J.} and Thiagarajan Ramcharan and Steven Paraskevas and Gillingham, {Kristen J.} and Dunn, {David L.} and Gruessner, {Rainer W G} and Abhinav Humar and Raja Kandaswamy and Najarian, {John S.} and Payne, {William D.} and Sutherland, {David E R}",
year = "2001",
month = "9",
doi = "10.1034/j.1600-6143.2001.001003278.x",
language = "English (US)",
volume = "1",
pages = "278--283",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation

T2 - A Pilot Study

AU - Matas, Arthur J.

AU - Ramcharan, Thiagarajan

AU - Paraskevas, Steven

AU - Gillingham, Kristen J.

AU - Dunn, David L.

AU - Gruessner, Rainer W G

AU - Humar, Abhinav

AU - Kandaswamy, Raja

AU - Najarian, John S.

AU - Payne, William D.

AU - Sutherland, David E R

PY - 2001/9

Y1 - 2001/9

N2 - Steroids are associated with significant postoperative complications (hypertension, cosmetic changes, bone loss, hyperlipidemia, diabetes, and cataracts). Most develop early; in addition, late post-transplant steroid withdrawal in kidney transplant recipients has been associated with increased acute rejection (AR). To obviate these problems, we studied outcome of a protocol of rapid discontinuation of prednisone (RDS) (steroids stopped on POD6). Between November 1, 1999 and October 31, 2000, 51 adult living donor (LD) first transplant recipients (2 HLA-id, 28 non-id relative, 21 LURD) were immunosuppressed with thymoglobulin (1.25 mg/kg intraoperatively and then qdx4); prednisone (P) (500 mg methylprednisolone intraoperatively, 1 mg/kg × 1 day, 0.5 mg/kg × 2 days, 0.25 mg/kg × 2days, then d/c); MMF, 1 g b.i.d.; and CSA, 4mg/kg b.i.d. adjusted to achieve levels of 150-200 ng/mL (by HPLC). Exclusion criteria were delayed graft function or 1° disease requiring P. Minimum follow-up was 5.5 months (range 5.5 to 17.5 months). Outcome was compared vs. previous cohorts of LD recipients immunosuppressed with P/AZA/ CSA (n=171) or P/MMF/CSA (n = 43) (both without antibody induction). Results: For the RDS group, average CSA level (±S.E.) at 3 and 6 months was 190±12 and 180±9; avg. MMF dose, 1.7±0.1 g and 1.7±0.1 g. There was no significant difference in 6- and 12-month actuarial patient survival, graft survival and rejection-free graft survival between recipients on the RDS protocol vs. historical controls. For RDS recipients, actuarial 6- and 12-month rejection-free graft survival was 87%. Of the 51 RDS recipients, five (10%) have had AR (at 20 days, 1 month, 3 months, 3 months, and 3.5 months post-transplant). After treatment, all five were maintained on 5mg P; there have been no second AR episodes. Two additional recipients were started on 5 mg P due to low white blood count (WBC) and low/no MMF. Of the 51 grafts, one has failed (death with function). Average serum Cr level (±S.E.) at 3 and 6 months for RDS recipients was 1.7±0.5 (NS vs. historical controls). Conclusion: For low-risk LD recipients, a kidney transplant with an RDS protocol does not increase risk of AR or graft loss. Future studies will need to be done to assess AR rates with an RDS protocol in cadaver transplant recipients and in recipients with delayed graft function.

AB - Steroids are associated with significant postoperative complications (hypertension, cosmetic changes, bone loss, hyperlipidemia, diabetes, and cataracts). Most develop early; in addition, late post-transplant steroid withdrawal in kidney transplant recipients has been associated with increased acute rejection (AR). To obviate these problems, we studied outcome of a protocol of rapid discontinuation of prednisone (RDS) (steroids stopped on POD6). Between November 1, 1999 and October 31, 2000, 51 adult living donor (LD) first transplant recipients (2 HLA-id, 28 non-id relative, 21 LURD) were immunosuppressed with thymoglobulin (1.25 mg/kg intraoperatively and then qdx4); prednisone (P) (500 mg methylprednisolone intraoperatively, 1 mg/kg × 1 day, 0.5 mg/kg × 2 days, 0.25 mg/kg × 2days, then d/c); MMF, 1 g b.i.d.; and CSA, 4mg/kg b.i.d. adjusted to achieve levels of 150-200 ng/mL (by HPLC). Exclusion criteria were delayed graft function or 1° disease requiring P. Minimum follow-up was 5.5 months (range 5.5 to 17.5 months). Outcome was compared vs. previous cohorts of LD recipients immunosuppressed with P/AZA/ CSA (n=171) or P/MMF/CSA (n = 43) (both without antibody induction). Results: For the RDS group, average CSA level (±S.E.) at 3 and 6 months was 190±12 and 180±9; avg. MMF dose, 1.7±0.1 g and 1.7±0.1 g. There was no significant difference in 6- and 12-month actuarial patient survival, graft survival and rejection-free graft survival between recipients on the RDS protocol vs. historical controls. For RDS recipients, actuarial 6- and 12-month rejection-free graft survival was 87%. Of the 51 RDS recipients, five (10%) have had AR (at 20 days, 1 month, 3 months, 3 months, and 3.5 months post-transplant). After treatment, all five were maintained on 5mg P; there have been no second AR episodes. Two additional recipients were started on 5 mg P due to low white blood count (WBC) and low/no MMF. Of the 51 grafts, one has failed (death with function). Average serum Cr level (±S.E.) at 3 and 6 months for RDS recipients was 1.7±0.5 (NS vs. historical controls). Conclusion: For low-risk LD recipients, a kidney transplant with an RDS protocol does not increase risk of AR or graft loss. Future studies will need to be done to assess AR rates with an RDS protocol in cadaver transplant recipients and in recipients with delayed graft function.

KW - Kidney transplant

KW - Steroid discontinuation

UR - http://www.scopus.com/inward/record.url?scp=18044399260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044399260&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2001.001003278.x

DO - 10.1034/j.1600-6143.2001.001003278.x

M3 - Article

C2 - 12102262

AN - SCOPUS:18044399260

VL - 1

SP - 278

EP - 283

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -